How A Broad Sell-Off Rattled Top 3% Breakout Stock Ligand Pharma

Core Viewpoint - Ligand Pharmaceuticals' stock has experienced a significant decline, dropping 7.8% to $204.04, which places it below its buy point of $212.49, amidst a broader market sell-off despite a positive report from BofA Securities [1]. Group 1 - Ligand Pharmaceuticals' shares fell into a sell zone after a breakout earlier in the week [1]. - The stock's decline occurred even with an upbeat report from BofA Securities, indicating potential underlying issues in the biotech sector [1]. - At one point, Ligand's stock experienced a notable drop, highlighting volatility in the biotech market [1].